Is Alzheimer’s disease different in people with Down’s? Two recent proteomics studies say yes. In the July 1 Nature Communications, scientists led by Erik Johnson at Emory University School of ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

Do you know a conference you think we should list? Let us know by sending us an email with the details to conferences@alzforum.org ...

Early onset familial Alzheimer disease (eFAD) is hereditary and marked by Alzheimer disease symptoms that appear at an unusually early age. Symptoms can start in a person's thirties, forties, and ...

This widely used tauopathy model was developed at the University of Pennsylvania School of Medicine by Virginia Lee, John Trojanowski, and colleagues. As first reported in 2007 on a mixed background, ...

Research News Parkinsonian disorders are difficult to diagnose. Clinical symptoms often overlap ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Introduction Despite being arguably the second most common dementing disorder, dementia with Lewy bodies, aka DLB, remains both mysterious and understudied. On Tuesday, October 10, 2017, the Lewy Body ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...